A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Phase 1 Recruiting
60 enrolled
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Phase 1 Completed
26 enrolled 19 charts
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Terminated
46 enrolled 12 charts
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
42 enrolled 10 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Terminated
22 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Terminated
40 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
Phase 3 Unknown
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Phase 1/2 Unknown
84 enrolled
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
18 enrolled
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Phase 1 Unknown
30 enrolled
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
Phase 2 Unknown
37 enrolled
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
Phase 3 Unknown
400 enrolled
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
Unknown
96 enrolled
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Phase 3 Completed
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Phase NA Terminated
30 enrolled
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Phase 1 Completed
64 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Phase 1 Completed
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Phase 1 Completed
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Perillyl Alcohol in Treating Patients With Refractory Cancer
Phase 1 Completed
25 enrolled
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
BMS-247550 in Treating Patients With Advanced Cancers
Phase 1 Completed
54 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
3 enrolled
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
45 enrolled
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Phase 2 Terminated
111 enrolled
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
72 enrolled